Physician profile
Andrew E Hardison
NPI 1770081465
$1,261.86
in general payments reported to CMS, 2019-2025
9 companies · $705 in 2025
The $705 reported for 2025 was more than what 79% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.64 · 2021: $76.73 · 2023: $206 · 2024: $196 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $354.42 | 2023-2025 | Infuse |
| Sight Sciences, INC. | $263.51 | 2024-2025 | Tearcare System, Omni Surgical System |
| Coopervision INC. | $191.87 | 2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $127.06 | 2023-2025 | Acuvue |
| New World Medical,INC. | $105.40 | 2025 | Streamline, Kahook Dual Blade, Via360 |
| Kala Pharmaceuticals, INC. | $77.64 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.73 | 2021 | |
| Alcon Vision LLC | $47.76 | 2024 | Total30 |
| Harrow Eye, LLC | $17.47 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hardison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.